Welcome to our dedicated page for Lipocine SEC filings (Ticker: LPCN), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Lipocine Inc.’s SEC filings document the regulatory record for a clinical-stage biopharmaceutical company focused on oral drug-delivery products. Recent 8-K filings furnish financial results, operational updates, corporate presentations and clinical disclosures for LPCN 1154 in postpartum depression, along with information on TLANDO licensing and royalty-related business activity.
The company’s filings also cover governance and capital-structure matters. Proxy materials describe annual meeting voting matters and board oversight, while current reports document board composition changes and common-stock offering documentation connected to an equity distribution arrangement. These filings frame Lipocine’s pipeline development, commercialization agreements, financing tools, risk disclosures and public-company governance.
Lipocine Inc. filed a current report describing a scientific presentation rather than a financial event. On May 26, 2026, the company presented Phase 3 clinical data for LPCN 1154, an oral brexanolone candidate for treating postpartum depression, at the American Society of Clinical Psychopharmacology Annual Meeting in Miami Beach.
The presentation and a related scientific poster, which summarize results from a placebo-controlled Phase 3 clinical trial in postpartum depression, are included as Exhibits 99.1 and 99.2 to the report and incorporated by reference for full clinical details.
Lipocine Inc. filed a current report describing a scientific milestone for its postpartum depression program. The company announced that Phase 3 clinical data for its oral brexanolone candidate LPCN 1154 have been selected for both oral and poster presentation at the 2026 American Society of Clinical Psychopharmacology (ASCP) Annual Meeting in Miami.
The oral presentation, titled “Novel Oral Rapid-Acting Neuroactive Steroid for Treatment of Postpartum Depression: A Placebo-Controlled Phase 3 Clinical Trial of LPCN 1154,” is scheduled for May 26, 2026. A related poster will be presented on May 27, 2026. Lipocine highlights LPCN 1154 as a non-SSRI, oral formulation of brexanolone designed as a rapid-acting treatment for postpartum depression with potential at-home use and no intensive monitoring requirement, and notes prior data suggesting improved tolerability and low central nervous system depressant side effects.
Lipocine Inc. filed a current report to note that its management will participate in a fireside chat at A.G.P.’s Annual Virtual Healthcare Company Showcase on Wednesday, May 20, 2026, at 3:00 PM.
The attached press release also highlights Lipocine’s oral drug-delivery focused pipeline, which includes candidates for postpartum depression, major depressive disorder, epilepsy, essential tremor, obesity management, liver cirrhosis symptoms, and prevention of preterm birth, as well as its FDA-approved oral testosterone product TLANDO for hypogonadism.
Lipocine Inc. reports a Schedule 13G showing Ikarian Capital and Neil Shahrestani jointly disclose ownership of 508,556 shares of Common Stock, representing 6.3% of the class.
The shares are held by Ikarian Healthcare Master Fund, L.P. and certain separately managed accounts; Ikarian Capital and Mr. Shahrestani state potential indirect beneficial ownership through investment discretion. The 6.3% calculation references 8,025,115 shares outstanding as of April 6, 2026.
Lipocine Inc. shareholders disclosed that Squadron Master Fund LP and affiliated reporting persons hold 450,000 shares of Common Stock, representing 6.2% of the class based on 7,299,687 shares outstanding as of 03/09/2026. The filing states the shares are held with shared voting and dispositive power among the Funds and named advisers/partners.
Lipocine Inc.
Lipocine Inc. reported first quarter 2026 results and a key clinical update. The Phase 3 trial of LPCN 1154, an oral brexanolone for postpartum depression, did not meet its primary endpoint of improving Hamilton Depression Rating Scale scores versus placebo at hour 60 in the full analysis set.
The drug was generally well tolerated with no treatment-related serious adverse events, excessive sedation, loss of consciousness, or treatment-related discontinuations. A post hoc analysis in participants with a history of psychiatric conditions showed statistically significant and clinically meaningful HAM-D improvements versus placebo, and Lipocine has applied for breakthrough therapy and fast track designations while evaluating next steps.
Financially, as of March 31, 2026, Lipocine held $24.7 million in unrestricted cash, cash equivalents and marketable investment securities. The company generated $119,397 in TLANDO royalty revenue and recorded a net loss of $3.7 million, or $(0.54) per diluted share, compared with a net loss of $1.9 million, or $(0.35) per share, a year earlier, largely driven by higher research and development spending on LPCN 1154.
Lipocine Inc. reported a larger net loss as it continued to invest in its pipeline while strengthening its balance sheet. For the three months ended March 31, 2026, total revenues were $119,397, all from TLANDO royalties, compared with $93,864 a year earlier.
The company’s net loss widened to $3.67 million from $1.86 million, driven mainly by higher research and development expense of $2.76 million versus $1.06 million as clinical programs advanced. General and administrative costs were stable at about $1.20 million.
Liquidity improved: cash and cash equivalents were $5.02 million and marketable investment securities $19.71 million, bringing total current assets to $25.24 million. During the quarter, Lipocine sold 1,314,138 shares via its at-the-market program, generating about $12.0 million in net proceeds, which helped lift stockholders’ equity to $22.83 million. Management believes existing capital resources will fund projected operating requirements through at least May 7, 2027, but it still anticipates needing additional financing over time to support development of its CNS and liver disease candidates.
Lipocine Inc. is asking stockholders to vote at its 2026 Annual Meeting on June 3, 2026 in Salt Lake City. Stockholders will elect four directors, ratify Tanner LLC as auditor for the year ending December 31, 2026, and cast an advisory “say‑on‑pay” vote on executive compensation.
The company also seeks approval to amend and restate its 2014 Stock and Incentive Plan, raising the annual individual award limit from 25,000 to 100,000 shares and increasing the total shares authorized for issuance under the plan from 600,000 to 1,000,000. As of the April 6, 2026 record date, 8,025,115 common shares were outstanding, and the Board unanimously recommends voting in favor of all proposals.
Lipocine Inc. reported that on April 16, 2026, Dr. Spyros Papapetropoulos resigned from its Board of Directors effective immediately. He had served since 2022 as Chairman, Lead Independent Director, and a member of the Board’s compensation committee.
The company stated that Dr. Papapetropoulos resigned due to competing professional commitments and evolving board dynamics arising from differing views on Lipocine’s strategic direction. On April 20, 2026, the Board appointed R. Dana Ono as the new Chairman of the Board and Lead Independent Director, ensuring continuity in independent board leadership.